Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]
BXCL701 is being studied in a Phase 1 trial for relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2,…
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML [Phase 2]
Phase 2 trial update evaluating total marrow and lymphoid irradiation plus chemotherapy before donor stem cell transplantation in high-risk …
-
CLINICAL_TRIALS research · 2025-07-17Clinical Trial Update: Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options? [Phase 2]
Phase 2 clinical trial is evaluating repurposed itraconazole as an adjuvant therapy for acute myeloid leukemia; the study is not yet recruit…
-
CLINICAL_TRIALS research · 2025-07-17Clinical Trial Update: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics [Phase 3]
A Phase 3 trial comparing standard intensive chemotherapy with CPX-351 versus standard therapy alone in adults with newly diagnosed acute my…
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece
An ongoing clinical trial in Greece is evaluating changes in disease state in adults with acute myeloid leukemia who are ineligible for inte…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-07-15Clinical Trial Update: A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients [Phase 2]
A Phase 2 clinical trial evaluating VA-CAG as induction therapy for newly diagnosed acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2025-07-15Clinical Trial Update: CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS [Phase 2]
Phase 2 trial status update for CPX-351 in older patients with refractory or relapsed acute myeloid leukemia and myelodysplastic syndromes; …
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia [NA]
This study explores whether patients with acute myeloid leukemia can safely measure blood counts at home and receive transfusions. It is cur…
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
This document provides an update on an ongoing Phase 1/Phase 2 clinical trial evaluating CD33-targeted CAR-T cells (CD33CART) in children an…
-
CLINICAL_TRIALS withdrawal · 2025-07-14Clinical Trial Update: TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant [NA]
A clinical trial evaluating TCRαβ/CD19-depleted stem cell grafts for transplantation has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-07-11Clinical Trial Update: Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 study of KITE-222 in relapsed/refractory acute myeloid leukemia has been terminated with trial results posted.
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Administration of Donor T Cells With the Caspase-9 Suicide Gene [Phase 1]
A Phase 1 trial evaluating donor T cells engineered with a caspase-9 suicide gene to enable controlled safety in hematologic diseases.
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Incidence and Risk Factors for the Development of Invasive Fungal Infection in Patients Diagnosed With Acute Myeloblastic Leukemia (HIFA)
This clinical trial update examines the incidence and risk factors for invasive fungal infections in patients diagnosed with acute myeloid l…
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling [Phase 1]
Phase 1 clinical trial evaluating ex vivo drug sensitivity testing and multi-omics profiling in pediatric cancers. Recruitment is ongoing ac…
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients [Phase 2]
A Phase 2 clinical trial update evaluating CPX-351 (Vyxeos) or CLAG-M regimen for acute myeloid leukemia or other high-grade myeloid neoplas…
-
CLINICAL_TRIALS other · 2025-07-10Clinical Trial Update: FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies [Phase 1]
Phase 1 trial update for FHD-286 as monotherapy or in combination in adults with advanced hematologic malignancies. The study is currently a…
-
CLINICAL_TRIALS trial_result · 2025-07-09Clinical Trial Update: AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 first-in-human study of AMG 176 in relapsed or refractory multiple myeloma and acute myeloid leukemia was terminated with results po…
-
CLINICAL_TRIALS trial_result · 2025-07-09Clinical Trial Update: Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating a proteasome inhibitor in combination with CPX-351 for newly diagnosed TP53-mutated acute myeloid leu…
-
CLINICAL_TRIALS research · 2025-07-09Clinical Trial Update: VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma [Phase 2]
Phase 2 clinical trial evaluating the VAM regimen in secondary acute myeloid leukemia, AML with extramedullary involvement, and myeloid sarc…
-
CLINICAL_TRIALS trial_result · 2025-07-08Clinical Trial Update: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96
A completed Italian observational study evaluating real-world outcomes of unfit acute myeloid leukemia patients treated with venetoclax in c…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome [Phase 1]
Phase 1 clinical trial of a radiolabeled anti-CD25 antibody with fludarabine, melphalan, and total marrow and lymphoid irradiation for high-…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant [Phase 2]
A Phase II randomized trial evaluating hyperbaric oxygen to improve engraftment after umbilical cord blood stem cell transplantation in pati…
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT [Phase 2]
This Phase 2 trial comparing post-transplant cyclophosphamide (PTCy) plus ruxolitinib versus PTCy with tacrolimus and MMF in matched related…
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep [Phase 2]
Phase 2 clinical trial evaluating non-myeloablative preparative regimens followed by umbilical cord blood transplantation for various hemato…
-
CLINICAL_TRIALS withdrawal · 2025-07-03Clinical Trial Update: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL [Phase 1]
The Phase 1 study of BMF-219, Biomea Fusion's covalent menin inhibitor, in adults with AML, ALL, DLBCL, multiple myeloma, and CLL/SLL has be…